Robert A. Bradway

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen ( AMGN )

Career :

Bradway joined Morgan Stanley in New York in 1985 as a health care industry investment banker. In 1990 he moved to London, where he served as managing director of Morgan Stanley with responsibility for the firm's banking department and corporate finance activities in Europe.

Bradway joined Amgen in 2006 as vice president of operations strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. He was its president and chief operating officer from May 2010 to May 2012. In October 2011, he was appointed to the Amgen board of directors. Bradway was named CEO of Amgen in May 2012, and chairman of the board in January 2013.

During Bradway’s tenure as CEO, Amgen's annual revenue increased from $17.3 billion in 2012 to $26 billion in 2021, and annual R&D investment increased to $4.2 billion in 2020. Bradway oversaw the acquisition of Iceland-based DeCODE Genetics in 2012, Onyx Pharmaceuticals in 2013, and a 20.5% equity stake in Beijing-based BeiGene in 2020.